As an expert in RNA and genome biology, John Rinn holds the title of Leslie Orgel Professor at the University of Colorado Boulder. John Rinn’s current research focuses on better understanding how the human genome is regulated. In 2016, while a Professor at Harvard University department of Stem Cell and Regenerative Biology he was selected by the Howard Hughes Medical Institute (HHMI) as an early career scientist for his research into a mysterious class of RNA genes called long noncoding RNAs (lncRNA). Professor Rinn was one of ten Harvard professors to receive the HHMI early career scientist award.
And also one of the four Harvard Stem Cell Institute (HSCI) faculty to receive the HHMI early career scientist award:
Founded in 2004, the Harvard Stem Cell Institute (HSCI) is dedicated to regenerative medicine and stem cell science. To this end, HSCI maintains eight affiliated hospitals and networks with more than 1000 Harvard-affiliated stem cell scientists. Recently, HSCI announced a five-year collaborative training and research agreement with Qatar Biomedical Research Institute (QBRI).
Through the agreement, the two research institutes will focus on stem cell biology with the intent to establish viable treatments for type 1 and type 2 diabetes, a healthcare challenge gaining in prevalence around the globe. Scientists will form joint research groups, exchange knowledge, and translate advancements into clinical applications. The collaboration hopes to ultimately assist patients with type 1 and type 2 diabetes better cope with their condition through the production of new insulin-producing cells.
As a HHMI early career scientist, John Rinn dedicates his research to RNA biology. Specifically, focusing on how long noncoding RNA (lncRNA) genes can play important biological roles as RNA molecules (rather than the more commonly studied protein based genes). John Rinn teaches courses at the University of Colorado Boulder as the Leslie Orgel Professor of RNA Science. Outside his basic research, John Rinn also serves on the editorial board of Genome Biology, a leading peer-reviewed, open-access scientific journal.
Genome Biology is committed to publishing exceptional research in all areas of biomedicine and biology studied through a post-genomic and genomic lens. For its work, Thomson Reuters listed Genome Biology the fourth-ranked journal in terms of impact in the Genetics and Heredity category. Here are several editorial and publishing practices at Genome Biology that have contributed to its status within the industry.
1. The journal has more than 46,000 followers on its Twitter account and is dedicated to promoting its content both through its social media presence, well-designed homepage, and press releases.
2. Committed to editorial transparency, Genome Biology publishes a peer reviewer report with every article it publishes. (This practice pertains to submissions starting on January 1, 2019.)
3. To better serve authors, reviewers, and readers, the journal maintains high standards of hospitality throughout the publishing process, including proactive communication on the progress of a manuscript.